Compare American Homes 4 Rent Class A (AMH) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Homes 4 Rent Class A vs Sanofi SA — how do they compare? American Homes 4 Rent Class A trades at $34.07 (market cap $12.28B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 8.5× American Homes 4 Rent Class A's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| AMH | SNY | |
|---|---|---|
Market Cap | $12.28B | $104.30B |
Sector | Real Estate | Health |
52-Week High | $35.82 | $52.34 |
52-Week Low | $27.38 | $41.33 |
Enterprise Value | $17.35B | $124.19B |
Dividend Yield | 3.87% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH (American Homes 4 Rent) trades at $33.87, down 0.76% today, with a bullish technical signal and strong fundamentals. The stock exhibits consistent earnings beats, with Q2 2026 FFO of $0.49 per share exceeding estimates (Zacks Investment Research, July 30, 2026). Revenue growth trends upward, reaching $1.85 billion in 2025, while net income margin improved to 25.53% in 2026. Recent news highlights institutional interest and raised 2026 guidance, supporting positive sentiment.
The outlook for AMH remains favorable due to robust operational performance and analyst consensus, but risks include regulatory changes affecting institutional home buying and high debt levels. With a $36.45 average price target and no sell ratings, Wall Street leans bullish, though investors should monitor housing policy impacts and interest rate sensitivity.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
